Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
05:38am, Wednesday, 24'th Jul 2024
Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
09:35am, Tuesday, 23'rd Jul 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09.
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
04:01pm, Tuesday, 16'th Jul 2024
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease
08:00am, Tuesday, 09'th Jul 2024
– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations –
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
08:30am, Monday, 17'th Jun 2024
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
04:01pm, Tuesday, 04'th Jun 2024
HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual G
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
04:01pm, Tuesday, 07'th May 2024
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
01:34pm, Wednesday, 24'th Apr 2024
Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-ye
Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript
01:59pm, Tuesday, 23'rd Apr 2024
Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA ) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief E
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
09:41am, Tuesday, 23'rd Apr 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.14.
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 23'rd Apr 2024
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million �
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
04:01pm, Tuesday, 16'th Apr 2024
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
07:30am, Tuesday, 02'nd Apr 2024
– Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
10:56am, Friday, 01'st Mar 2024
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd.
01:01pm, Thursday, 29'th Feb 2024
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?
